Jaya Agnihotri, Priyanka Maurya, Shobhna Singh and Shubhini A. Saraf* Pages 3 - 15 ( 13 )
Background: Cytotherapy products can be described as “living drugs”. Cytotherapy is the swiftest growing fields in the treatment of cancer, heart diseases, aging population and neuromuscular ailments. Biomimetic approaches are processes developed by humans such as devices, substances, or systems that mimic nature or natural processes.
Objective and Method: It aims at developing a base for personalized medicine with allogeneic, autologous and xenogenic therapies where cells are modified for target selection. Such drug delivery methods appear to be complex and challenging. Literature for approximately past two decades was collected and reviewed for the present article.
Results and Conclusion: The opportunities and challenges in cytotherapy have been classified, discussed and demystified. Various process inputs, materials and process conditions required in bioprocessing and preservation have been discussed at length. The review also focuses on the regulatory requirements in India, Europe and U.S.
Cytotherapy, bioprocessing, regulatory requirements, biomimetic, nanomedicine, allogeneic.
H.K. College of Pharmacy, Jogeshwari West, Mumbai, Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), VidyaVihar, Raebareli Road, Lucknow, 226025, M.J.P.Rohilkhand University, Bareilly (U.P.), Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), VidyaVihar, Raebareli Road, Lucknow, 226025